Expanded access to zidesamtinib for advanced ROS1-positive cancer
Part of Cancer, Lungs & breathing clinical trials.
This program provides access to an experimental drug (zidesamtinib) for people with advanced ROS1-positive cancer who have run out of other options. The study aims to give these patients a chance to try a new targeted therapy that may help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer has a ROS1 gene change (ROS1 rearrangement) and has spread or is advanced.
- You have already tried at least one ROS1 targeted therapy drug.
- You are not able to join a clinical trial for this drug, but there is no other good treatment option for you.
- Your body's organs and bone marrow are working well enough for this treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial gives access to an investigational drug called zipalertinib for people with a specific type of advanced lung cancer (EGFR exon 20 insertion) who have already tried chemotherapy. The goal is to see if the drug can help control the cancer when other treatments have stopped working.
This study looks at how well a targeted therapy works for people with advanced non-small cell lung cancer that has a specific genetic change called ROS1. It aims to see if this treatment can help control the cancer and improve outcomes.
This trial tests an oral drug called DZD6008 for people with advanced non-small cell lung cancer (NSCLC) that has certain EGFR mutations. It may be an option for those who have tried other EGFR treatments or are new to treatment.
This study gathers real-world experience with the targeted drug taletrectinib for people with a specific type of advanced lung cancer (ROS1-positive) that has spread to the brain. Participation may help doctors better understand how well the drug works in everyday practice.
This trial tests whether adding a new drug (zoldonrasib) to standard chemotherapy and immunotherapy can help people with a specific type of lung cancer. It is for those with a RAS G12D mutation and no prior treatment for metastatic disease.
This study compares a new targeted therapy pill (taletrectinib) to standard treatments for people with advanced ROS1-positive lung cancer. The goal is to see if taletrectinib works better at shrinking tumors and delaying cancer growth.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.